Your browser doesn't support javascript.
loading
Could the chylomicron marker apoB48 be of value in the diagnosis of chylous effusions?
Lefrère, Bertrand; Sakka, Mehdi; Fourati, Salma; Levasseur, Antoine; Curis, Emmanuel; Cherfils, Corinne; Grès, Pierre; Guilbert, Zoé; Lacorte, Jean-Marc; Chenevière, Cristina; Bittar, Randa; Bonnefont-Rousselot, Dominique.
Afiliação
  • Lefrère B; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie métabolique, Paris, France. Electronic address: bertrand.lefrere@aphp.fr.
  • Sakka M; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie métabolique, Paris, France.
  • Fourati S; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie endocrinienne et oncologique, Paris, France.
  • Levasseur A; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie métabolique, Paris, France.
  • Curis E; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; EA 7537 BioSTM, Faculté de Pharmacie, Université Paris Descartes, USPC, Paris 75006, France.
  • Cherfils C; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie métabolique, Paris, France.
  • Grès P; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie métabolique, Paris, France.
  • Guilbert Z; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie métabolique, Paris, France.
  • Lacorte JM; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie endocrinienne et oncologique, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Unité de recherche sur les maladies cardiovasculaires et métaboliques, UMR 1166 ICAN, Sorbonne Université, Inserm, Paris, France.
  • Chenevière C; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie endocrinienne et oncologique, Paris, France.
  • Bittar R; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie métabolique, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Unité de recherche sur les maladies cardiovasculaires et métaboliques, UMR 1166 ICAN, Sorbonne Université, Inserm, Paris, France.
  • Bonnefont-Rousselot D; AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Service de Biochimie métabolique, Paris, France; UFR de Pharmacie, Université Paris Cité; CNRS, Inserm, UTCBS, Paris, France.
Clin Chim Acta ; 539: 184-190, 2023 Jan 15.
Article em En | MEDLINE | ID: mdl-36463939
ABSTRACT

BACKGROUND:

Chylous effusions such as chylothorax, chylopericardium and chylous ascites are marked by the abnormal presence of chylomicrons in serous membranes. These relatively rare situations are associated with high morbidity and mortality rates. Given that a macroscopic assessment of the fluid is insufficient, the current gold standard method for chylous effusion is the electrophoretic separation of lipoproteins. Serous effusions are most frequently assayed for triglycerides, with a diagnostic threshold varying between studies. The present study is the first to assess the value of the apolipoprotein B48, specific of the chylomicron, in the diagnosis of chylous effusions.

METHODS:

A chemiluminescent sandwich enzyme immunoassay was used to measure levels of apoB48 in remnant samples of effusion fluid sent to our laboratory for chylomicron detection and lipid assays. The diagnostic values of apoB48 and triglyceride assays were compared with that of the gold standard method.

RESULTS:

The triglyceride and apoB48 levels and the triglyceride/cholesterol ratio in the effusion fluid were significantly higher in patients with chylous effusion. The threshold values for apoB48 were respectively 2.45, 0.25 and 19.00 µg/mL for a maximal Youden index, a sensitivity > 95 %, and a specificity > 95 %. The apoB48 assay's diagnostic value might be at least as high as that of a triglyceride assay (area under the receiver operating characteristic curve [95 % confidence interval] 0.84 [0.72, 0.96]) and 0.80 [0.67, 0.94], respectively).

CONCLUSION:

ApoB48 appears to be a promising marker for the diagnosis of chylous effusions; the putative diagnostic improvement must be confirmed in larger studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Derrame Pleural / Quilotórax Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Derrame Pleural / Quilotórax Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article